Your browser doesn't support javascript.
loading
Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis.
de Coo, Ilse F; Marin, Juana Ca; Silberstein, Stephen D; Friedman, Deborah I; Gaul, Charly; McClure, Candace K; Tyagi, Alok; Liebler, Eric; Tepper, Stewart J; Ferrari, Michel D; Goadsby, Peter J.
Afiliação
  • de Coo IF; 1 Leiden University Medical Centre, Leiden, the Netherlands.
  • Marin JC; 2 NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, UK.
  • Silberstein SD; 3 Department of Neurology, Jefferson Headache Center, Philadelphia, PA, USA.
  • Friedman DI; 4 Department of Neurology, University of Texas Southwestern, Dallas, TX, USA.
  • Gaul C; 5 Migraine and Headache Clinic, Königstein, Germany.
  • McClure CK; 6 North American Science Associates Inc., Minneapolis, MN, USA.
  • Tyagi A; 7 Neurology Department, The Southern Hospital, Glasgow, UK.
  • Liebler E; 8 electroCore, Inc., Basking Ridge, NJ, USA.
  • Tepper SJ; 9 Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • Ferrari MD; 1 Leiden University Medical Centre, Leiden, the Netherlands.
  • Goadsby PJ; 2 NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, UK.
Cephalalgia ; 39(8): 967-977, 2019 Jul.
Article em En | MEDLINE | ID: mdl-31246132
ABSTRACT

BACKGROUND:

Two randomized, double-blind, sham-controlled trials (ACT1, ACT2) evaluated non-invasive vagus nerve stimulation (nVNS) as acute treatment for cluster headache. We analyzed pooled ACT1/ACT2 data to increase statistical power and gain insight into the differential efficacy of nVNS in episodic and chronic cluster headache.

METHODS:

Data extracted from ACT1 and ACT2 were pooled using a fixed-effects model. Main outcome measures were the primary endpoints of each study. This was the proportion of participants whose first treated attack improved from moderate (2), severe (3), or very severe (4) pain intensity to mild (1) or nil (0) for ACT1 and the proportion of treated attacks whose pain intensity improved from 2-4 to 0 for ACT2.

RESULTS:

The pooled population included 225 participants (episodic n = 112; chronic n = 113) from ACT1 (n = 133) and ACT2 (n = 92) in the nVNS (n = 108) and sham (n = 117) groups. Interaction was shown between treatment group and cluster headache subtype (p < 0.05). nVNS was superior to sham in episodic but not chronic cluster headache (both endpoints p < 0.01). Only four patients discontinued the studies due to adverse events.

CONCLUSIONS:

nVNS is a well-tolerated and effective acute treatment for episodic cluster headache. TRIAL REGISTRATION The studies were registered at clinicaltrials.gov (ACT1 NCT01792817; ACT2 NCT01958125).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Estudos Multicêntricos como Assunto / Cefaleia Histamínica / Estimulação do Nervo Vago Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Estudos Multicêntricos como Assunto / Cefaleia Histamínica / Estimulação do Nervo Vago Idioma: En Ano de publicação: 2019 Tipo de documento: Article